Moneycontrol
    Moneycontrol PRO

    Jump to

    • EXCLUSIVE: Kiran Mazumdar-Shaw asks govt to let companies use CSR funds to vaccinate employees

    • Mechanics of Modicare: The health scheme fine print

    • Partnership with Sandoz is for the future wave of biosimilars: Biocon

    • TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study

    • Trastuzumab approval is a milestone: Biocon

    • EMA communication with regards to Trastuzumab does not mean an approval: Biocon

    • It wouldn't be wise to change Biocon's EPS estimate with CRL received: Nirmal Bang

    • Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO

    • Expect Malaysian unit to contribute 3/4th of insulin biz revenue going ahead: Biocon

    • Biocon seeks withdrawal of application for two biosimilars under European drug regulator review

    • Will try & ask for re-inspection at the earliest, says Biocon

    • Countdown to GST: Find out how India Inc views its impacts

    • To cut healthcare costs, US must partner India: Biocon's Shaw

    • Biocon to see inspections by USFDA & EMA in April-May: Sources

    • Biocon chief sees anti-cancer biosimilar launch in FY19

    • I don't see Trump's views affecting Indian drug cos: Biocon CMD

    • Speciality offers better returns, says Biocon Chief

    • Demonetisation has impacted Indian sales, not exports: Biocon

    • Half of US stunned, other half exhilarated with Trump win: Shaw

    • Public health a worry; privatisation a must: Kiran Mazumdar Shaw

    • Trastuzumab marketing approval may come in 12-18 months: Biocon

    • Pharma cos have increased focus on quality controls: Biocon CMD

    • Drug to treat eye disease won't hit mkt before 2-3 yrs: Biocon

    • FDI in pharma via automatic route a welcome step: Biocon

    • Biocon-Mylan to file 4 drug applications in FY17 under rev-share

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347